相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
Shengli Xia et al.
LANCET INFECTIOUS DISEASES (2021)
Nanomaterial Delivery Systems for mRNA Vaccines
Michael D. Buschmann et al.
VACCINES (2021)
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Zhiwei Wu et al.
LANCET INFECTIOUS DISEASES (2021)
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Yanjun Zhang et al.
LANCET INFECTIOUS DISEASES (2021)
Signaling Through Nucleic Acid Sensors and Their Roles in Inflammatory Diseases
Haruna Okude et al.
FRONTIERS IN IMMUNOLOGY (2021)
Emerging concepts in the science of vaccine adjuvants
Bali Pulendran et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants
Sachin Bhagchandani et al.
ADVANCED DRUG DELIVERY REVIEWS (2021)
Targeting Toll-like receptor 3 in dendritic cells for cancer immunotherapy
Misako Matsumoto et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Molecular mechanisms and cellular functions of cGAS-STING signalling
Karl-Peter Hopfner et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
Mark J. Mulligan et al.
NATURE (2020)
Small molecule agonists of toll-like receptors 7 and 8: a patent review 2014-2020
Madeleine E. Kieffer et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2020)
Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
Tsun-Yung Kuo et al.
SCIENTIFIC REPORTS (2020)
RIG-I-like receptors: their regulation and roles in RNA sensing
Jan Rehwinkel et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations A Double-Blind, Placebo-controlled, Dose-Selection Trial
Sara Suliman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines
Kimberly J. Hassett et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2019)
The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation
Nathan Kelley et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Flagellin/NLRC4 Pathway Rescues NLRP3-Inflammasome Defect in Dendritic Cells From HIV-Infected Patients: Perspective for New Adjuvant in Immunocompromised Individuals
Edione Cristina dos Reis et al.
FRONTIERS IN IMMUNOLOGY (2019)
An R848 adjuvanted influenza vaccine promotes early activation of B cells in the draining lymph nodes of non-human primate neonates
Beth C. Holbrook et al.
IMMUNOLOGY (2018)
Extrinsic Phagocyte-Dependent STING Signaling Dictates the Immunogenicity of Dying Cells
Jeonghyun Ahn et al.
CANCER CELL (2018)
Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice
Hussein Sultan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Flagellin as a vaccine adjuvant
Baofeng Cui et al.
EXPERT REVIEW OF VACCINES (2018)
A Two-Dose Hepatitis B Vaccine for Adults (Heplisav-B) (Reprinted from The Medical Letter on Drugs and Therapeutics vol 60, pg 17-18, 2018)
Mark Abramowicz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
mRNA vaccines - a new era in vaccinology
Norbert Pardi et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31 (R) in people living in a TB-endemic area
Jemal Hussein et al.
TRIALS (2018)
Vaccine adjuvant ARNAX promotes mucosal IgA production in influenza HA vaccination
Yohei Takeda et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations
Silvia Sanchez-Ramon et al.
FRONTIERS IN IMMUNOLOGY (2018)
Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want
Harm HogenEsch et al.
NPJ VACCINES (2018)
Enhancing immunotherapy of STING agonist for lymphoma in preclinical models
Adrienne Sallets et al.
BLOOD ADVANCES (2018)
Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer
Heather L. Kinkead et al.
JCI INSIGHT (2018)
The Syk-NFAT-IL-2 Pathway in Dendritic Cells Is Required for Optimal Sterile Immunity Elicited by Alum Adjuvants
Hanif Javanmard Khameneh et al.
JOURNAL OF IMMUNOLOGY (2017)
A New RNA-Based Adjuvant Enhances Virus-Specific Vaccine Responses by Locally Triggering TLR- and RLH-Dependent Effects
Annett Ziegler et al.
JOURNAL OF IMMUNOLOGY (2017)
Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response
Darin K. Edwards et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Efficient Targeting and Activation of Antigen Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques
Frank Liang et al.
MOLECULAR THERAPY (2017)
H1:IC31 vaccination is safe and induces long-lived TNF-α+IL-2+CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: krandomized trial
Helen Mearns et al.
VACCINE (2017)
Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials
Maria Norrby et al.
VACCINE (2017)
Targeting Pattern Recognition Receptors (PRR) for Vaccine Adjuvantation: From Synthetic PRR Agonists to the Potential of Defective Interfering Particles of Viruses
Andri Vasou et al.
VIRUSES-BASEL (2017)
A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy
Yohei Takeda et al.
CELL REPORTS (2017)
AS03-and MF59-Adjuvanted influenza vaccines in Children
Amanda L. Wilkins et al.
FRONTIERS IN IMMUNOLOGY (2017)
Lysosome-Dependent Activation of Human Dendritic Cells by the Vaccine Adjuvant QS-21
Iain Welsby et al.
FRONTIERS IN IMMUNOLOGY (2017)
Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity
Margherita Coccia et al.
NPJ VACCINES (2017)
Monophosphoryl lipid A induces protection against LPS in medullary thick ascending limb through a TLR4-TRIF-PI3K signaling pathway
Bruns A. Watts et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2017)
Non-clinical safety evaluation of repeated intramuscular administration of the AS15 immunostimulant combined with various antigens in rabbits and cynomolgus monkeys
N. Gacron et al.
JOURNAL OF APPLIED TOXICOLOGY (2016)
Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants
Robyn Marty-Roix et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Tumor vaccines with dsRNA adjuvant ARNAX induces antigen-specific tumor shrinkage without cytokinemia
Tsukasa Seya et al.
ONCOIMMUNOLOGY (2016)
Inflammasome Complexes: Emerging Mechanisms and Effector Functions
Vijay A. K. Rathinam et al.
CELL (2016)
Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma
Sofie Wilgenhof et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Natural STING Agonist as an Ideal Adjuvant for Cutaneous Vaccination
Ji Wang et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Xing Liu et al.
NATURE (2016)
Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing
Qi Chen et al.
NATURE IMMUNOLOGY (2016)
An inflammatory response is essential for the development of adaptive immunity-immunogenicity and immunotoxicity
Tetsuo Nakayama
VACCINE (2016)
Central Role of CD169+ Lymph Node Resident Macrophages in the Adjuvanticity of the QS-21 Component of AS01
Sophie Detienne et al.
SCIENTIFIC REPORTS (2016)
Harnessing the beneficial heterologous effects of vaccination
Helen S. Goodridge et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate
Zoltan Beck et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2015)
STING Activation by Translocation from the ER Is Associated with Infection and Autoinflammatory Disease
Nicole Dobbs et al.
CELL HOST & MICROBE (2015)
MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside
Burghardt Wittig et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
Nikolai Petrovsky
DRUG SAFETY (2015)
N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice
Oliwia Andries et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands as Influenza Virus Vaccine Adjuvants Induce Rapid, Sustained, and Broadly Protective Responses
Peter H. Goff et al.
JOURNAL OF VIROLOGY (2015)
Pediatric Vaccine Adjuvants Components of the Modern Vaccinologist's Toolbox
David J. Dowling et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2015)
Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo
Misako Matsumoto et al.
NATURE COMMUNICATIONS (2015)
Vaccine adjuvant uses of poly-IC and derivatives
Karen Ao Martins et al.
EXPERT REVIEW OF VACCINES (2015)
Identification of Aim2 as a Sensor for DNA Vaccines
John J. Suschak et al.
JOURNAL OF IMMUNOLOGY (2015)
Delivering HIV Gagp24 to DCIR Induces Strong Antibody Responses In Vivo
Anne-Laure Flamar et al.
PLOS ONE (2015)
Microbial Sensing by Toll-Like Receptors and Intracellular Nucleic Acid Sensors
Surya Pandey et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2015)
Vaccine Adjuvants: from 1920 to 2015 and Beyond
Alberta Di Pasquale et al.
VACCINES (2015)
Flagellin Induces Antibody Responses through a TLR5-and Inflammasome-Independent Pathway
Americo Harry Lopez-Yglesias et al.
JOURNAL OF IMMUNOLOGY (2014)
Toll-Like Receptor 7/8 (TLR7/8) and TLR9 Agonists Cooperate To Enhance HIV-1 Envelope Antibody Responses in Rhesus Macaques
M. Anthony Moody et al.
JOURNAL OF VIROLOGY (2014)
Cyclic GMP-AMP Displays Mucosal Adjuvant Activity in Mice
Ivana Skrnjug et al.
PLOS ONE (2014)
Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans
Edgar Turner Overton et al.
VACCINE (2014)
A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7
Christopher B. Fox et al.
JOURNAL OF NANOBIOTECHNOLOGY (2014)
STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer
Dinesh Chandra et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Genuine Immunomodulation With dSLIM
Kerstin Kapp et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2014)
Toll-like receptor signaling pathways
Takumi Kawasaki et al.
FRONTIERS IN IMMUNOLOGY (2014)
Adjuvants That Improve the Ratio of Antigen-Specific Effector to Regulatory T Cells Enhance Tumor Immunity
Rachel Perret et al.
CANCER RESEARCH (2013)
The history of MF59 (R) adjuvant: a phoenix that arose from the ashes
Derek T. O'Hagan et al.
EXPERT REVIEW OF VACCINES (2013)
The use of Toll-like receptor 7/8 agonists as vaccine adjuvants
John P. Vasilakos et al.
EXPERT REVIEW OF VACCINES (2013)
Full-Length Plasmodium falciparum Circumsporozoite Protein Administered with Long-Chain Poly(I.C) or the Toll-Like Receptor 4 Agonist Glucopyranosyl Lipid Adjuvant-Stable Emulsion Elicits Potent Antibody and CD4+ T Cell Immunity and Protection in Mice
Kathrin Kastenmueller et al.
INFECTION AND IMMUNITY (2013)
Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses
S. B. Rizwan et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Vaccine Injection Site Matters: Qualitative and Quantitative Defects in CD8 T Cells Primed as a Function of Proximity to the Tumor in a Murine Glioma Model
John R. Ohlfest et al.
JOURNAL OF IMMUNOLOGY (2013)
Type I IFN Counteracts the Induction of Antigen-Specific Immune Responses by Lipid-Based Delivery of mRNA Vaccines
Charlotte Pollard et al.
MOLECULAR THERAPY (2013)
The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination
Maria Vono et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA
Jiaxi Wu et al.
SCIENCE (2013)
Vaccine adjuvant formulations: A pharmaceutical perspective
Luis A. Brito et al.
SEMINARS IN IMMUNOLOGY (2013)
Improved CD4(+) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial
Isabel Leroux-Roels et al.
VACCINE (2013)
STING-Dependent Recognition of Cyclic di-AMP Mediates Type I Interferon Responses during Chlamydia trachomatis Infection
Jeffrey R. Barker et al.
MBIO (2013)
A novel, disruptive vaccination technology Self-adjuvanted RNActive® vaccines
Karl-Josef Kallen et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Malaria Vaccine Adjuvants: Latest Update and Challenges in Preclinical and Clinical Research
Elena Mata et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Mechanisms of action of adjuvants
Sunita Awate et al.
FRONTIERS IN IMMUNOLOGY (2013)
Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes
Evan A. Scott et al.
BIOMATERIALS (2012)
Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates
Marcin Kwissa et al.
BLOOD (2012)
Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
Paul Sabbatini et al.
CLINICAL CANCER RESEARCH (2012)
The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses
Andres Mori et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion
Nathalie Garcon et al.
EXPERT REVIEW OF VACCINES (2012)
Antigen depot is not required for alum adjuvanticity
Sharon Hutchison et al.
FASEB JOURNAL (2012)
Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro
Tirth R. Ghimire et al.
IMMUNOLOGY LETTERS (2012)
A Comparative Study of Stress-mediated Immunological Functions with the Adjuvanticity of Alum
Yufei Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Influence of formulation pH and suspension state on freezing-induced agglomeration of aluminum adjuvants
Maya S. Salnikova et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Sensing and reacting to microbes through the inflammasomes
Luigi Franchi et al.
NATURE IMMUNOLOGY (2012)
Phase 1 Study in Malaria Naive Adults of BSAM2/Alhydrogel®+CPG 7909, a Blood Stage Vaccine against P. falciparum Malaria
Ruth D. Ellis et al.
PLOS ONE (2012)
STING Specifies IRF3 Phosphorylation by TBK1 in the Cytosolic DNA Signaling Pathway
Yasuo Tanaka et al.
SCIENCE SIGNALING (2012)
Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection
Seol Hee Hong et al.
VACCINE (2012)
The mechanism of action of MF59 - An innately attractive adjuvant formulation
D. T. O'Hagan et al.
VACCINE (2012)
ATP release and purinergic signaling: a common pathway for particle-mediated inflammasome activation
N. Riteau et al.
CELL DEATH & DISEASE (2012)
Anthrax Lethal Factor Cleavage of Nlrp1 Is Required for Activation of the Inflammasome
Jonathan L. Levinsohn et al.
PLOS PATHOGENS (2012)
Trained Immunity: A Memory for Innate Host Defense
Mihai G. Netea et al.
CELL HOST & MICROBE (2011)
An Adjuvanted Polyprotein HIV-1 Vaccine Induces Polyfunctional Cross-Reactive CD4+ T Cell Responses in Seronegative Volunteers
Eva Van Braeckel et al.
CLINICAL INFECTIOUS DISEASES (2011)
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Nathalie Garcon et al.
EXPERT REVIEW OF VACCINES (2011)
An Unexpected Role for Uric Acid as an Inducer of T Helper 2 Cell Immunity to Inhaled Antigens and Inflammatory Mediator of Allergic Asthma
Mirjam Kool et al.
IMMUNITY (2011)
Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets
Kathrin Kastenmueller et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans
Marina Caskey et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity
Mariola Fotin-Mleczek et al.
JOURNAL OF IMMUNOTHERAPY (2011)
The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus
Yue Zhao et al.
NATURE (2011)
Immunological mechanisms of vaccination
Bali Pulendran et al.
NATURE IMMUNOLOGY (2011)
Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity
Tracy L. Flach et al.
NATURE MEDICINE (2011)
Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88
Anja Seubert et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59
Ali H. Ellebedy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates
Barbara J. Flynn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice
Lidice Bernardo et al.
VACCINE (2011)
Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes
Samuele Calabro et al.
VACCINE (2011)
Bis-(3′,5′)-cyclic dimeric adenosine monophosphate: Strong Th1/Th2/Th17 promoting mucosal adjuvant
Thomas Ebensen et al.
VACCINE (2011)
Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity
Sandra Morel et al.
VACCINE (2011)
The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system
Abbi L Engel et al.
Expert Review of Clinical Pharmacology (2011)
TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin
Matam Vijay-Kumar et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection
Karen Smith Korsholm et al.
IMMUNOLOGY (2010)
The Capacity To Induce Cross-Presentation Dictates the Success of a TLR7 Agonist-Conjugate Vaccine for Eliciting Cellular Immunity
Jason Z. Oh et al.
JOURNAL OF IMMUNOLOGY (2010)
Intranasal Administration of Adjuvant-Combined Vaccine Protects Monkeys From Challenge With the Highly Pathogenic Influenza A H5N1 Virus
Takeshi Ichinohe et al.
JOURNAL OF MEDICAL VIROLOGY (2010)
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Taro Kawai et al.
NATURE IMMUNOLOGY (2010)
Immunopotentiation of Trivalent Influenza Vaccine When Given with VAX102, a Recombinant Influenza M2e Vaccine Fused to the TLR5 Ligand Flagellin
H. Keipp Talbot et al.
PLOS ONE (2010)
Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults
John J. Treanor et al.
VACCINE (2010)
Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response
Stephanie M. Noe et al.
VACCINE (2010)
Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems
Isabel Leroux-Roels et al.
VACCINE (2010)
3′,5′-Cyclic diguanylic acid elicits mucosal immunity against bacterial infection
Hongbin Yan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
There is an association between contact allergy to aluminium and persistent subcutaneous nodules in children undergoing hyposensitization therapy
Eva Netterlid et al.
CONTACT DERMATITIS (2009)
Characterization of the freeze sensitivity of a hepatitis B vaccine
Dexiang Chen et al.
HUMAN VACCINES (2009)
The roles of TLRs, RLRs and NLRs in pathogen recognition
Taro Kawai et al.
INTERNATIONAL IMMUNOLOGY (2009)
Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant
M. Paula Longhi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity
Arnaud M. Didierlaurent et al.
JOURNAL OF IMMUNOLOGY (2009)
Host Responses from Innate to Adaptive Immunity after Vaccination: Molecular and Cellular Events
Sang-Moo Kang et al.
MOLECULES AND CELLS (2009)
AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC
Veit Hornung et al.
NATURE (2009)
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Hiroki Ishikawa et al.
NATURE (2009)
PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants
Takeshi Ichinohe et al.
VACCINE (2009)
MF59®-adjuvanted influenza vaccine (FLUAD®) in children: Safety and immunogenicity following a second year seasonal vaccination
T. Vesikari et al.
VACCINE (2009)
Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants
LaToya Jones Braun et al.
VACCINE (2009)
A clinical grade poly I:C-analogue (Ampligen (R)) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro
H. Navabi et al.
VACCINE (2009)
Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant
C. R. Casella et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
Alum adjuvanticity: Unraveling a century old mystery
Ennio De Gregorio et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells
Mirjam Kool et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Targeting Poly(I:C) to the TLR3-Independent Pathway Boosts Effector CD8 T Cell Differentiation through IFN-α/β
Soo M. Ngoi et al.
JOURNAL OF IMMUNOLOGY (2008)
The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells
Anja Seubert et al.
JOURNAL OF IMMUNOLOGY (2008)
Cutting edge: Inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3
Hanfen Li et al.
JOURNAL OF IMMUNOLOGY (2008)
Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability
Katalin Kariko et al.
MOLECULAR THERAPY (2008)
TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines
Ken J. Ishii et al.
NATURE (2008)
Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants
Stephanie C. Eisenbarth et al.
NATURE (2008)
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Hiroki Ishikawa et al.
NATURE (2008)
Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization
Veit Hornung et al.
NATURE IMMUNOLOGY (2008)
Molecular and cellular signatures of human vaccine adjuvants
F. Mosca et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers
Pierre Vandepapeliere et al.
VACCINE (2008)
Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy
Mazin Barry et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women:: an interim analysis of a phase III double-blind, randomised controlled trial
Jorma Paavonen et al.
LANCET (2007)
Activation of dendritic cells and induction of CD4+ T cell differentiation by aluminum-containing adjuvants
Anna Sokolovska et al.
VACCINE (2007)
The dsRNA protein kinase PKR:: Virus and cell control
M. A. Garcia et al.
BIOCHIMIE (2007)
TLR3 is essential for the induction of protective immunity against Punta Toro virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not poly(I:C):: Differential, recognition of synthetic dsRNA molecules
Brian B. Gowen et al.
JOURNAL OF IMMUNOLOGY (2007)
New hepatitis B vaccine formulated with an improved adjuvant system
Michael Kundi
EXPERT REVIEW OF VACCINES (2007)
Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity
James W. Huleatt et al.
VACCINE (2007)
Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses
Tarun K. Ghosh et al.
CELLULAR IMMUNOLOGY (2006)
Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation
Cristiana Guiducci et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses
Carola Schellack et al.
VACCINE (2006)
Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1β in salmonella-infected macrophages
Luigi Franchi et al.
NATURE IMMUNOLOGY (2006)
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses
H Kato et al.
NATURE (2006)
Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
DM Harper et al.
LANCET (2006)
IFN-α/β-dependent cross-priming induced by specific toll-like receptor agonists
V Durand et al.
VACCINE (2006)
Critical role for NALP3/CIAS1/cryopyrin in innate and adaptive immunity through its regulation of caspase-1
FS Sutterwala et al.
IMMUNITY (2006)
Pathogen recognition and innate immunity
S Akira et al.
CELL (2006)
A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity
SE Lee et al.
INFECTION AND IMMUNITY (2006)
RNase L: Its biological roles and regulation
Shu-Ling Liang et al.
IUBMB LIFE (2006)
HIV Gag protein conjugated to a toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates
U Wille-Reece et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Interferon-β induction through Toll-like receptor 3 depends on double-stranded RNA structure
S Okahira et al.
DNA AND CELL BIOLOGY (2005)
Vaccines for tuberculosis: Novel concepts and recent progress
TM Doherty et al.
CLINICAL MICROBIOLOGY REVIEWS (2005)
CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in anti retroviral-treated HIV-infected adults
CL Cooper et al.
AIDS (2005)
Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection
GA Kolumam et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer
MR Weihrauch et al.
CLINICAL CANCER RESEARCH (2005)
Separation and quantification of a novel two-component vaccine adjuvant
CE Kritsch et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2005)
Toll-like receptor 3 promotes cross-priming to virus-infected cells
O Schulz et al.
NATURE (2005)
Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type
AC Rimaniol et al.
VACCINE (2004)
Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques
P Silvera et al.
VACCINE (2004)
Toll-like receptors: linking innate and adaptive immunity
C Pasare et al.
MICROBES AND INFECTION (2004)
Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities
J Vollmer et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
DM Harper et al.
LANCET (2004)
A subset of toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells
SK Datta et al.
JOURNAL OF IMMUNOLOGY (2003)
The roles of toll-like receptor 9, MyD88, and DNA-depondent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets
H Hemmi et al.
JOURNAL OF IMMUNOLOGY (2003)
The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5
F Hayashi et al.
NATURE (2001)
Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs
D Verthelyi et al.
JOURNAL OF IMMUNOLOGY (2001)
分享论文
